Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692210 · ClinicalTrials.gov registry record
The Effect of Dexmedetomidine of the Immune System
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 20
- Enrollment target
NCT01692210: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT01692210 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01692210 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The goal of this research study is to learn about how dexmedetomidine (a standard of care sedative) affects your immune system (your defenses against cancer) by measuring your white blood cell levels before and after surgery.
Primary Outcome
Lymphocyte counts determined by flow-cytometry and their function by cytotoxicity assays performed in the laboratory using samples obtained before and the morning after surgery. Patients who experience a reduction of less than 50% of their preoperative natural killer cell (NKC) activity considered as a success.
Interventions
- DRUG Dexmedetomidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-02 |
What the finished NCT01692210 record still lists
NCT01692210 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dexmedetomidine is the first listed.
NCT01692210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01692210 about?
NCT01692210 is a clinical study titled "The Effect of Dexmedetomidine of the Immune System". The goal of this research study is to learn about how dexmedetomidine (a standard of care sedative) affects your immune system (your defenses against cancer) by measuring your white blood cell levels before and after surgery.
What is the current status of trial NCT01692210?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2012-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01692210?
The interventions under investigation include: Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT01692210?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia